BOLLÉ-SAFETY
19.4.2021 10:32:04 CEST | Business Wire | Press release
Global eye protection specialist Bollé Safety now provides Trivex. A high-performance, high-technology prescription lens providing maximum security and great optical properties to ensure the best safety in a work environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210419005013/en/
The best of CR39 and polycarbonate in addition to unique features.
Bollé Safety’s latest lens material combines CR39’s lightness and polycarbonate’s durability. With a featherweight density (1,11g/cm3), Trivex is the lightest corrective lens material on the market. It also offers very good optical properties, superior to polycarbonate. The Trivex technology corrects some drawbacks traditionally attached to CR39 and polycarbonate. The lens is 20% thinner than CR39 and is shatterproof. Unlike polycarbonate, it is chemical and solvent resistant, making it safe to operate in a variety of work environments. Special new features include a 100% efficient UV filter that absorbs the totality of UVA and UVB for even better eye protection. And to ensure long-lasting aesthetics, the lens doesn’t turn yellow over time.
Why go to Bollé Safety to switch to Trivex?
Trivex properties are so high-performing that its technology was initially used for military purposes. With half of the global population over 20 years old suffering from vision problems, companies have a crucial interest in providing their workers with safety prescription eyewear that ensures optimal protection. Poor vision can lead to massive productivity losses and classic safety eyewear is not a one-size-fits-all product. Did you know that 90% of eye injuries could be prevented with proper protection and care? Wearing adapted and fitted eyewear can be a game-changer for professionals. Bollé Safety offers several ranges of products for plano and prescription lenses, so everyone can have perfect vision and safe working conditions. Bollé Safety’s latest frames, “KLASSEE” and “KURT”, make the most out of the Trivex technology. Thanks to Bollé’s unique global expertise, the KLASSEE model combines bio-sourced materials with side protections on the top and on the bottom of the frames. KURT is a great option with adjustable reinforced arms and an athletic frame for even more protection. The translucent front has been smoked to optimize side vision without being blinded. Lightweight and flexible, Bollé Safety glasses ensure a comfortable and secure experience and diminish risks in the work environment.
For more information, visit https://bit.ly/3e0A43j
About Bollé Safety.
Bollé Safety, the global brand for eye protection. Over our 130 years of existence, we have created more than 500 models of safety glasses. With a wide range of innovative, comfortable, and protective safety and prescription eyewear, we are trusted with the protection of over 20 million workers’ vision in 100 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005013/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom